APC-Cy7 Mouse Anti-Human CD16 Antibody (S-R440)

產(chǎn)品型號：S0B5508

更新時間：2025-10-09

廠商性質(zhì)：生產(chǎn)廠家

訪問量：141

服務(wù)熱線

15855403091

立即咨詢

產(chǎn)品分類

PRODUCT CLASSIFICATION

抗體/抗原

ELISA試劑盒抗體試劑盒二抗試劑盒二抗其它流式抗體瓊脂糖/磁珠偶聯(lián)抗體抗Payload抗體泛修飾抗體標簽/內(nèi)參抗體功能性抗體 Biosimilar抗體偶聯(lián)抗體配對抗體病理/IHC抗體

查看全部產(chǎn)品

相關(guān)文章

流式抗體封閉：如何有效避免實驗中的假陽性結(jié)果？

腸道黏蛋白 MUC2：從黏液屏障到疾病開關(guān)的雙重身份解碼

如何利用PD-1抗體在免疫學與腫瘤治療研究中取得突破？

抗獨特型抗體如何成為抗體藥物研發(fā)的關(guān)鍵工具？

產(chǎn)品介紹

CD16, also known as FcγRIII, is a type of glycoprotein belonging to the immunoglobulin superfamily. It is divided into two subtypes: CD16a （FcγRIIIa） and CD16b （FcγRIIIb）. CD16a is a transmembrane protein mainly expressed on natural killer （NK） cells, monocytes, and some T cell subsets, while CD16b is a GPI-anchored protein primarily found on neutrophils. CD16a can mediate antibody-dependent cell cytotoxicity （ADCC） by binding to the Fc region of IgG antibodies, which is crucial for the immune system to eliminate virus-infected cells and cancer cells. Additionally, CD16a is one of the core markers for defining NK cells and can promote their proliferation and secretion of cytotoxic cytokines. In cancer immunotherapy, CD16a is an important target protein, and some monoclonal antibody drugs are designed to enhance its binding ability to boost immune responses.

上一個：S0B5509APC-Cy7 Rat Anti-Mouse CD8α Antibody (S-353-45)